Advertisement

Antiarrhythmic Therapy to Prevent Atrial Fibrillation after Cardiac Surgery

  • Bradley P. Knight
  • Fred Morady
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 222)

Abstract

Cardiac surgery and the postoperative state are associated with increased catecholamine levels [1]. Therefore, beta-blockers are logical agents to prevent atrial fibrillation in this setting. Indeed, many trials have shown a benefit with prophylactic beta-blockade [2-9]. However, the data regarding beta-blockers must be interpreted with caution. Some of the apparent benefit of beta-blockers may be explained by beta-blocker withdrawal in patients assigned to placebo. In addition, many of the beta-blocker trials excluded patients with left ventricular dysfunction and obstructive lung disease, and patients undergoing concomitant valvular surgery. Because of the limitations of beta-blockers and because there is a significant incidence of postoperative atrial fibrillation despite beta-blocker prophylaxis, other pharmacological approaches to prevent postoperative atrial fibrillation have been investigated.

Keywords

Atrial Fibrillation Coronary Artery Bypass Grafting Antiarrhythmic Drug Postoperative Atrial Fibrillation Supraventricular Tachyarrhythmia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaiman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G, Tonkin AM. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 1995;60:1709–15.CrossRefGoogle Scholar
  2. 2.
    Daudon P, Corcos T, Gandjbakhch I, Levasseur J, Cabrol A, Cabrol C. Prevention of atrial fibrillation or flutter by acebutolol after coronary bypass grafting. Am J Cardiol 1986;58:933–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Silverman NA, Wright R, Levitsky S. Efficacy of low-dose propranolol in preventing postoperative supraventricular tachyarrhythmias. A prospective, randomized study. Ann Surg 1982;196:194–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Abel RM, van Gelder HM, Pores IH, Liguori J, Gielchinsky I, Parsonnet V. Continued propranolol administration following coronary bypass surgery. Arch Surg 1983;118:727–31.PubMedGoogle Scholar
  5. 5.
    Martinussen HJ, Lolk A, Szczepanski C, Alstrup P. Supraventricular tachyarrhythmias after coronary bypass surgery-A double blind randomized trial of prophylactic low dose propranolol. Thorac cardiovasc Surgeon 1988;36:206–7.CrossRefGoogle Scholar
  6. 6.
    Ivey MF, Ivey TD, Bailey WW, Williams DB, Hessel EA, Miller DW. Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. J Thorac Cardiovasc Surg 1983; 85:214–18.PubMedGoogle Scholar
  7. 7.
    Shafie H, Nashef SAM, Turner MA, Bain WH. Does low-dose propranolol reduce the incidence of supraventricular tachyarrhythmias following myocardial revascularization? — A clinical study. Thorac cardiovasc Surgeon 1988;36:202–5.CrossRefGoogle Scholar
  8. 8.
    White HD, Antman EM, Glynn MA, Collins JJ, Cohn LH, Shemin RJ, Friedman PL. Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. Circulation 1984;70:479–84.PubMedGoogle Scholar
  9. 9.
    Lamb RK, Prabhakar G, Thorpe JAC, Smith S, Norton R, Dyde JA. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur Heart J 1988;9:32–36.PubMedGoogle Scholar
  10. 10.
    Johnson LW, Dickstein RA, Fruehan CT, Kane P, Potts JL, Smulyan H, Webb WR, Eich RH. Prophylactic digitalization for coronary artery bypass surgery. Circulation 1976;53:819–22.PubMedGoogle Scholar
  11. 11.
    Tyras DH, Stothert JC, Kaiser GC, Barner HB, Codd JE, Willman VL. Supraventricular tachyarrhythmias after myocardial revascularization: A randomized trial of prophylactic digitalization. J Thorac Cardiovasc Surg. 1979;77:310–4.PubMedGoogle Scholar
  12. 12.
    Csicsko JF, Schatzlein MH, King RD. Immediate postoperative digitalization in the prophylaxis of supraventricular arrhythmias following coronary artery bypass. J Thorac Cardiovasc Surg 1981;81:419–22.PubMedGoogle Scholar
  13. 13.
    Chee TP, Prakash NS, Desser KB, Benchimol A. Postoperative supraventricular arrhythmias and the role of prophylactic digoxin in cardiac surgery. Am Heart J 1982;104:974–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Fanning WJ, Thomas CS, Roach A, Tomichek R, Alford WC, Stoney WS. Prophylaxis of atrial fibrillation with magnesium sulfate after coronary artery bypass grafting. Ann Thorac Surg 1991;52:529–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Parikka H, Toivonen L, Pellinen T, Verkkala K, Jarvinen A, Nieminen MS. The influence of intravenous magnesium sulphate on the occurrence of atrial fibrillation after coronary artery by-pass operation. Eur Heart J 1993;14:251.PubMedGoogle Scholar
  16. 16.
    Davison R, Hartz R, Kaplan K, Parker M, Feiereisel P, Michaelis L. Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: A randomized, double-blind trial. Ann Thorac Surg 1985;39:336–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Laub GW, Janeira L, Muralidharan S, Riebman JB, Chen C, Neary M, Fernandez J, Adkins MS, McGrath LB. Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: A prospective, double-blind, randomized, placebo-controlled pilot study. Critic Care Med 1993;21:1474–8.CrossRefGoogle Scholar
  18. 18.
    Janssen J, Loomans L, Harink J, Taams M, Brunninkhuis L, van der Starre P, Kootstra G. Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: A randomized open trial. J Vasc Dis 1986;37:601–9.Google Scholar
  19. 19.
    Suttorp MJ, Kingma JH, Tjon Joe Gin RM, van Hemel NM, Koomen EM, Defauw JA, Adan AJM, Ernst SM. Efficacy and safety of low-and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovas Surg 1990;100:921–6.Google Scholar
  20. 20.
    Suttorp MJ, Kingma JH, Peels HOJ, Koomen EM, Tifssen JGP, van Hemel NM, Defauw JAM, Emst SMPG. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991;68:1163–69.CrossRefPubMedGoogle Scholar
  21. 21.
    Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. Thorac cardiovasc Surgeon 1993; 41:34–37.CrossRefGoogle Scholar
  22. 22.
    Parikka H, Toivonen L, Heikkila L, Virtanen K, Jarvinan A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol 1998;31:67–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jamhnchen E, Zehender M, Fraedrich G, Just H. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: Results of a prospective, placebo-controlled study. Am Heart J 1991;121:89–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Butler J, Harriss DR, Sinclair M, Westaby S. Amiodarone prophylaxis for tachycardias after coronary artery surgery: A randomised, double blind, placebo controlled trial. Br Heart J 1993;70:56–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Guarnieri T. Amiodarone Reduces CABG Hospitalization (ARCH) trial. Presented as a Late Breaking Clinical Trial at the 47th Annual Scientific Session of the American College of Cardiology. March 1998.Google Scholar
  26. 26.
    Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Boiling SF, Pagani FD, Bitar C, Meissner MD, Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. NEJM 1997;337:1785–91.CrossRefPubMedGoogle Scholar
  27. 27.
    The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. European Heart Journal 1997;18:649–54.Google Scholar
  28. 28.
    Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954–1968.PubMedGoogle Scholar
  29. 29.
    Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Morady F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600–1606.PubMedGoogle Scholar
  30. 30.
    Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, Strickberger SA, Morady F. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997;5:1542–5019.Google Scholar
  31. 31.
    Packer M, O’Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. NEJM. 1996;335:1107–1114.CrossRefPubMedGoogle Scholar
  32. 32.
    Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856–63.PubMedGoogle Scholar
  33. 33.
    The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. NEJM. 1988;319:385–392.CrossRefGoogle Scholar
  34. 34.
    Cheng JW, Behar L. Calcium channel blockers: association with myocardial infarction, mortality, and cancer. [Review]. Clinical Therapeutics 1997;19:1255–68.CrossRefPubMedGoogle Scholar
  35. 35.
    Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ, Cohn LH, Burstin HR. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996;94:390–97.PubMedGoogle Scholar
  36. 36.
    Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553–58.CrossRefPubMedGoogle Scholar
  37. 37.
    ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. 1SIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–85.CrossRefGoogle Scholar
  38. 38.
    Baxter GF, Sumeray MS, Walker JM. Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet 1996; 348: 1424–26.CrossRefPubMedGoogle Scholar
  39. 39.
    Chun S, Sager P, Stevenson W, Nademanee K, Middlekauff H, Singh B. Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. J Am Coll Cardiol 1993;21:203A.Google Scholar
  40. 40.
    Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:75F–81F.CrossRefPubMedGoogle Scholar
  41. 41.
    Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289–93.CrossRefPubMedGoogle Scholar
  42. 42.
    Mason JW, Amiodarone. N Engl J Med 1987;316:455–66.CrossRefPubMedGoogle Scholar
  43. 43.
    Hondeghem LM. Class III agents: amiodarone, bretylium, and sotalol. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: WB. Saunders, 1995:1330–6.Google Scholar
  44. 44.
    Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14:1768–74.CrossRefPubMedGoogle Scholar
  45. 45.
    Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122:1016–21.CrossRefPubMedGoogle Scholar
  46. 46.
    Ayers GM, Rho TH, Ben-David J, Besch HR Jr, Zipes DP. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. Journal of Cardiovascular Electrophysiology 1996;7:713–21.CrossRefPubMedGoogle Scholar
  47. 47.
    Labhasetwar V, Levy RJ. Novel delivery of antiarrhythmic agents. (Review) Clinical Pharmacokinetics 1995;29:1–5.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Bradley P. Knight
    • 1
  • Fred Morady
    • 1
  1. 1.The University of Michigan Medical CenterAnn Arbor

Personalised recommendations